Double Bond Pharmaceutical AB (publ) ("DBP") announces that a scientific abstract regarding its lead product candidate, Temodex, has been accepted for presentation at the upcoming Congress of the European Association of Neurosurgical Societies (EANS) 2026.
The presentation will provide a comprehensive dive into the final analysis of the company's Real-World Evidence (RWE) study, offering granular insights into various patient cohorts. As previously disclosed, the final analysis of this RWE study reinforces that Temodex delivers a clinically significant survival benefit in the treatment of glioblastoma.
"We have previously confirmed that the integration of Temodex into the treatment regimen resulted in a survival increase of 5.6 months," stated Igor Lokot, CEO of Double Bond Pharmaceutical. "We look forward to presenting these RWE results in greater depth, particularly regarding specific cohorts where we have observed even more profound therapeutic outcomes. The EANS Congress serves as a premier global forum for neurosurgery, providing an ideal environment to engage with international experts as we advance our global expansion strategy".
More about Real-World Evidence Study: https://mb.cision.com/Main/12720/4341704/4064687.pdf
More about EANS2026 Congress: https://eanscongress.org/
More about SI-053: SI-053, an enhanced reformulation of Temodex, is a locally acting formulation of temozolomide. SI-053 received Orphan Drug Designation from the European Medicines Agency in 2016 and received multiple Competent Authority and Ethics Committee approvals from 2021 to 2023 to initiate a Phase 1 clinical study. In a proof-of-concept study with human subjects conducted in 2015, SI-053 demonstrated significant overall survival benefit when added to the standard of care for glioblastoma. Video presentation: https://youtu.be/iweOQPq316o
Information about Double Bond Pharmaceutical AB: DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company's own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. Double Bond Pharmaceutical acquired rights to Temodex in October 2015, and was granted Orphan Drug Designation status by EMA for in July 2016 for this formulation of temozolomide for the treatment of glioma. The formulation is now being further developed for registration in EU and globally and has a working name SI-053 in DBP pipeline.
Full Company Name: Double Bond Pharmaceutical International AB (publ)
Corporate identity: 556991-6082
Stock short name: DBP B
Share ISIN code: SE0007185525
For more info, contact
Igor Lokot, CEO
Homepage: http://www.doublebp.com/
E-mail: info@doublebp.com
Follow us on LinkedIn